Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) – Pipeline Review, H2 2020’, provides in depth analysis on Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System and Dermatology under development targeting Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)

– The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics and enlists all their major and minor projects

– The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Baergic Bio Inc

Cerevel Therapeutics LLC

NeuroCycle Therapeutics Inc

Saniona AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Overview

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Companies Involved in Therapeutics Development

Baergic Bio Inc

Cerevel Therapeutics LLC

NeuroCycle Therapeutics Inc

Saniona AB

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Drug Profiles

BAER-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVL-865 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-711 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Dormant Products

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Discontinued Products

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Product Development Milestones

Featured News & Press Releases

Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy

Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865

Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigational Epilepsy treatment

Feb 18, 2019: Sanionas SAN711 selected for clinical studies in itching and pain

Feb 13, 2019: NeuroCycle Therapeutics receives NIH SBIR Grant to study Dravet Syndrome drug candidate NCT10004

Dec 04, 2017: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indications, H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Products under Development by Companies, H2 2020 (Contd..3), H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Actavalon Inc, H2 2020

Pipeline by Active Biotech AB, H2 2020

Pipeline by Ampio Pharmaceuticals Inc, H2 2020

Pipeline by AnTolRx Inc, H2 2020

Pipeline by Bayer AG, H2 2020

Pipeline by Dermavant Sciences Inc, H2 2020

Pipeline by Hercules Pharmaceuticals BV, H2 2020

Pipeline by Hutchison MediPharma Ltd, H2 2020

Pipeline by Ikena Oncology Inc, H2 2020

Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020

Pipeline by Magenta Therapeutics Inc, H2 2020

Pipeline by Pfizer Inc, H2 2020

Pipeline by Phenex Pharmaceuticals AG, H2 2020

Pipeline by Shenogen Pharma Group Ltd, H2 2020

Pipeline by Sol-Gel Technologies Ltd, H2 2020

Pipeline by Welichem Biotech Inc, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports